Physician profile
Aigul Schultz
NPI 1609501980
$715.69
in general payments reported to CMS, 2019-2025
20 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $312 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $135.42 | 2024-2025 | Akeega, Erleada, Rybrevant |
| Phathom Pharmaceuticals, INC. | $90.87 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $54.80 | 2024-2025 | Libtayo |
| Geron Corporation | $52.95 | 2025 | Rytelo |
| Hologic Sales and Service, LLC | $32.68 | 2024 | Aptima |
| Coherus Oncology, INC. | $32.41 | 2024 | |
| Novartis Pharmaceuticals Corporation | $28.47 | 2025 | |
| Abbvie INC. | $28.25 | 2025 | |
| Incyte Corporation | $27.37 | 2025 | Monjuvi, Zynyz |
| Lilly USA, LLC | $26.02 | 2025 | Jaypirca, Verzenio |
| Pharmacosmos Therapeutics INC. | $25.25 | 2025 | Monoferric |
| Spectrum Pharmaceuticals INC. | $23.59 | 2025 | Rolvedon |
| Merck Sharp & Dohme LLC | $23.00 | 2025 | Keytruda |
| Daiichi Sankyo INC. | $22.83 | 2024 | Enhertu |
| Myriad Genetic Laboratories, INC. | $20.38 | 2024 | Myrisk |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19.91 | 2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $19.23 | 2025 | Empliciti |
| Acrotech Biopharma INC. | $19.17 | 2024 | Beleodaq |
| Kowa Pharmaceuticals America, INC. | $18.12 | 2024 | Zoryve |
| Ipsen Biopharmaceuticals, INC | $14.97 | 2024 | Somatuline Depot, Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aigul Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.